Workshop on «Essential» Phospholipids in the Treatment of Diabetes Mellitus and Dyslipidemias

A scientific and practical symposium Essential phospholipids in the treatment of diabetes mellitus and dyslipidemia organized by RON-PULENK RORER (Cologne, Germany) was held at the State Central Scientific Medical Library of the Ministry of Health of Russia. The basic concept of the development of dyslipidemia (DLP) and the working classification of this metabolic state were presented in a report by Yu. A. Knyazev (Moscow). In the message K. Gundermann et al. (Cologne, Germany) the mechanism of action of essential phospholipids (EPL) at the molecular level, the level of insulin receptor and postreceptor interactions in cytomembranes, as well as in lipolytic and cholinesterizing enzyme systems was described. The feasibility of using EPL preparations for the prevention of diabetic angiopathies (AP) by transplanting pancreatic incretory cell cultures, with conservative and surgical treatment of AP with the aim of stabilizing or even reversing the development of atherosclerotic vascular lesions, was substantiated in a report by A. A. Chirkin et al. (Vitebsk, Belarus). The results of the study of intravascular microcirculation in patients with diabetes with clinical signs of AP made it possible to evaluate lipostabil (a drug containing EPL and prescribed together with hypoglycemic agents) as an effective tool in the plasma-cell type of microcirculatory disorders in patients with diabetes aged 19 to 68 years (I. M Kakhnovsky et al., Moscow). Under the influence of lipostabil forte, an increase in insulin sensitivity is possible (L. L. Vakhrusheva et al., Moscow), which underlies a decrease in the need for exogenous insulin and a tendency to normalize indicators of carbohydrate and fat metabolism, the level of counterinsulin hormones. 6 months after the start of lipostabil forte administration, an inhibition of AP progression was noted against the background of an adequate dose of insulin.

Download Full-text

Free-radical oxidation, antioxidants, and diabetic angiopathies

Problems of Endocrinology ◽

10.14341/probl12052 ◽

1996 ◽

Vol 42 (6) ◽

pp. 14-20 ◽

Cited By ~ 1

Author(s):

L. E. Bobyreva

Keyword(s):

Diabetes Mellitus ◽

Free Radical ◽

Free Radical Oxidation ◽

Vascular Lesions ◽

Diabetic Angiopathies ◽

Radical Oxidation ◽

Number Of Patients ◽

Patients With Diabetes ◽

The One

The leading pathology in endocrinology is diabetes mellitus, which is characterized by a high incidence of disability and high mortality. According to the data of A. G. Mazovetsky, by 2000 compared with 1985, an increase in the number of patients with diabetes mellitus is expected to be 2.9 times. The frequency of vascular lesions in diabetes is 6891.3%. The results of D. Greene indicate that peripheral vascular damage in this group of patients is observed 30 times more often than in people of a similar age without diabetes mellitus. Free radical pathology. Recent studies of domestic and foreign authors indicate the important role of non-enzymatic free radical oxidation (FRO) of lipids in the pathogenesis of many chronic diseases of modern man. Before analyzing the role of free radical mechanisms in the pathogenesis of diabetes mellitus and diabetic angiopathies, it is necessary to briefly familiarize yourself with the general ideas about the nature of FRO lipids and their inhibition systems. Due to the spin properties of triplet oxygen, when it interacts with a pair of donor electrons, the probability of free radical formation is high. The one-electron form of reduced oxygen can be protonated НО2*(hydroperoxyl radical) and anionic О2- (superoxide radical).

Download Full-text

Hypoglycaemia in the treatment of diabetes mellitus

Oxford Textbook of Endocrinology and Diabetes ◽

10.1093/med/9780199235292.003.1435 ◽

2011 ◽

pp. 1849-1861

Author(s):

Pratik Choudhary ◽

Stephanie A. Amiel

Keyword(s):

Diabetes Mellitus ◽

Blood Glucose ◽

Blood Glucose Concentration ◽

Cerebral Metabolism ◽

Chronic Complications ◽

Glucose Levels ◽

Patients With Diabetes ◽

Treatment Of Diabetes ◽

Clinically Significant ◽

The Brain

Hypoglycaemia (low blood glucose concentration) is the most important acute complication of the pharmacological treatment of diabetes mellitus. Low blood glucose impairs brain (and, potentially, cardiac) function. The brain has minimal endogenous stores of energy, with small amounts of glycogen in astroglial cells. The brain is therefore largely dependent on circulating glucose as the substrate to fuel cerebral metabolism and support cognitive performance. If blood glucose levels fall sufficiently, cognitive dysfunction is inevitable. In health, efficient glucose sensing and counterregulatory mechanisms exist to prevent clinically significant hypoglycaemia. These are impaired by diabetes and by its therapies. Patients with diabetes rank fear of hypoglycaemia as highly as fear of chronic complications such as nephropathy or retinopathy (1). Fear of hypoglycaemia, hypoglycaemia itself and attempts to avoid hypoglycaemia limit the degree to which glycaemic control can be intensified to reduce the risk of chronic complications of diabetes both for type 1 and type 2 diabetes.

Download Full-text

Nursing patients with endocrine problems

Oxford Handbook of Adult Nursing ◽

10.1093/med/9780199231355.003.0010 ◽

2009 ◽

pp. 303-326

Keyword(s):

Diabetes Mellitus ◽

Thyroid Surgery ◽

Diagnostic Tests ◽

Nursing Interventions ◽

Endocrine Gland ◽

Nursing Management ◽

Nursing Assessment ◽

Patients With Diabetes ◽

Treatment Of Diabetes

Hormones 304 Nursing assessment of patients with endocrine problems 306 Diagnostic tests 308 Endocrine gland disorders 310 Thyroid surgery 314 Diabetes mellitus 316 Presentation and treatment of diabetes 318 Nursing management of the patient with diabetes who is admitted to hospital 320 Nursing interventions for patients with diabetes ...

Download Full-text

Design and Estimation of Fast Dissolving Tablet by using Novel Techniques for Effective Treatment of Diabetes

International Journal of Engineering and Advanced Technology - Regular Issue ◽

10.35940/ijeat.b3636.029320 ◽

2020 ◽

Vol 9 (3) ◽

pp. 2345-2349

Keyword(s):

Diabetes Mellitus ◽

Blood Glucose ◽

Pancreatic Islets ◽

Protein Digestion ◽

Lipid Digestion ◽

Diabetes Mellitus Type Ii ◽

Insulin Reaction ◽

Patients With Diabetes ◽

Treatment Of Diabetes ◽

Postprandial Insulin

Diabetes mellitus is a metabolic issue it is brought about by a flat out or relative absence of insulin that, among different outcomes, increments in plasma glucose fixation related to change hyperglycemia and unsettling influence of lipid digestion, starch digestion, additionally protein digestion. Glipizide, a secondgen sulfonylurea, is utilized with diet to bring down blood glucose in patients with diabetes mellitus type II. The essential method of activity of glipizide in exploratory creatures seems, by all accounts, to be the incitement of insulin emission from the beta cells of pancreatic islet tissue and is in this way reliant on working -cells in the pancreatic islets. In human's glipizide seems to bring down the blood glucose intensely by invigorating the arrival of insulin from the pancreas, an impact subordinate after working -cells in the pancreatic islets. In man, incitement of insulin discharge by glipizide because of a feast is undoubtedly vital. Fasting insulin levels are not raised even on long haul glipizide organization, yet the postprandial insulin reaction keeps on being upgraded after at any rate a half year of treatment.

Download Full-text

Prevalence of combined atherosclerotic vascular lesions in patients with diabetes mellitus

Diabetes Mellitus ◽

10.14341/2072-0351-5979 ◽

2012 ◽

Vol 15 (1) ◽

pp. 49-55 ◽

Cited By ~ 1

Author(s):

Svetlana Alexandrovna Gracheva ◽

Inna Igorevna Klefortova ◽

Minara Shamkhalovna Shamkhalova

Keyword(s):

Diabetes Mellitus ◽

Risk Factors ◽

Renal Artery ◽

Cardiovascular Complications ◽

Vascular Lesions ◽

Acute Complications ◽

Patients With Diabetes ◽

Progression Of Disease ◽

Aggressive Care ◽

Rule Out

During latest decade, as threat of acute complications of diabetes mellitus was surmounted, cardiovascular complications became leadingcause of death. Clinical manifestation of coronary, brachiocephalic and renal atherosclerosis is quite dramatic in diabetes mellitus,which determines extent of dissemination and intensity of lesions. Combination of these mutually confounding conditions is a characteristicproblem of patients with diabetes mellitus. Presence of 2+ risk factors (one of which is diabetes mellitus in itself) requiresactive examination in order to rule out coronary, brachiocephalic, peripheral and renal artery lesions. Aggressive care is necessaryin order to control progression of disease and administer adequate conservative and endovascular treatment with account of high riskof combination of lesions.

Download Full-text

Analysis of oral hypoglycemic agents in the normative documents regulating the treatment of diabetes mellitus 2 type

Upravlìnnâ ekonomìka ta zabezpečennâ âkostì v farmacìï ◽

10.24959/uekj.16.33 ◽

2016 ◽

Vol 0 (3(47)) ◽

pp. 75-80

Author(s):

L. V. Yakovleva ◽

A. L. Bilyk

Keyword(s):

Diabetes Mellitus ◽

Hypoglycemic Agents ◽

Oral Hypoglycemic Agents ◽

Normative Documents ◽

Treatment Of Diabetes ◽

Diabetes Mellitus 2

Download Full-text

Diabetes und Herzinsuffizienz

Diabetologie und Stoffwechsel ◽

10.1055/a-0876-5672 ◽

2019 ◽

Vol 14 (03) ◽

pp. 180-192

Author(s):

Philipp H. Baldia ◽

Nikolaus Marx ◽

Katharina A. Schütt

Keyword(s):

Diabetes Mellitus ◽

Heart Failure ◽

Early Stage ◽

Hospitalization Rates ◽

Patients With Heart Failure ◽

Patients With Diabetes ◽

Treatment Of Diabetes ◽

The Common ◽

Current Guidelines ◽

Positive Effect

AbstractDiabetes mellitus is a very important comorbidity in patients with heart failure, as the common presence of both diseases significantly worsens the prognosis of patients. In order to improve the outcome of these patients, it is essential to diagnose both diseases at an early stage and to treat them in accordance with guidelines. In particular, a differentiated medication plays a crucial role. The therapy of heart failure does not differ in patients with diabetes and patients without diabetes. In the treatment of diabetes mellitus, however, it is very important to choose substances that have a positive effect on the cardiovascular outcome of patients. First-line treatment of diabetes in patients with cardiovascular diseases should be metformin, followed by a SGLT-2 inhibitor or GLP-1 receptor agonist with proven cardiac benefit. A rigorous adjustment of risk factors according to current guidelines reduces cardiovascular mortality and hospitalization rates. Glitazones and saxagliptin are associated with increased hospitalization rates and should be avoided in heart failure.

Download Full-text

An Overview on Anti Diabetic Drugs and Development

Science & Technology Journal ◽

10.22232/stj.2016.04.02.05 ◽

2016 ◽

Vol 4 (2) ◽

pp. 113-123 ◽

Cited By ~ 3

Author(s):

Ved Prakash Singh ◽

Keyword(s):

Diabetes Mellitus ◽

The United States ◽

Insulin Analogues ◽

Hypoglycemic Agents ◽

Oral Hypoglycemic Agents ◽

Related Complication ◽

Glucose Levels ◽

Blood Glucose Levels ◽

Target Organs ◽

Treatment Of Diabetes

Diabetes mellitus is one of the world’s major diseases and is the third leading cause of death in the United States after heart disease and cancer. In the India, about 2–6% population suffer from diabetes or related complication. Anti-diabetic drugs treat diabetes mellitus by lowering glucose levels in the blood. Mostly anti-diabetic drugs are administered orally except the insulin, exenatide, and pramlintide. There are different types of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, and many other factors. Treatments include the agents which increase the amount of insulin secreted by the pancreas, or increase the sensitivity of target organs to insulin, and agents which decrease the rate at which glucose is absorbed from the gastrointestinal tract. People are mainly focused on insulin, insulin analogues, oral hypoglycemic agents and various other complementary and alternate medicines to control the blood glucose levels in diabetes. The present review summarizes in brief about the drugs used for treatment of diabetes mellitus.

Download Full-text

Momordica charantia Extracts in Selected Media:Screening of Phytochemical Content and In vitro Evaluation of Anti-Diabetic Properties

The Indian Journal of Nutrition and Dietetics ◽

10.21048/ijnd.2016.53.2.4297 ◽

2016 ◽

Vol 53 (2) ◽

pp. 164 ◽

Cited By ~ 3

Author(s):

Flora-Glad Chizoba Ekezie ◽

W. Jessie Suneetha ◽

K. Uma Maheswari ◽

T. N. V. K. V. Prasad ◽

B. Anila Kumari

Keyword(s):

Diabetes Mellitus ◽

Citric Acid ◽

Ethanol Extract ◽

Momordica Charantia ◽

Bitter Gourd ◽

Phytochemical Content ◽

Patients With Diabetes ◽

Potential Applications ◽

Treatment Of Diabetes

Diabetes mellitus is a multifunctional disorder which is increasing rapidly in most parts of the world. It has been estimated that up to one third of patients with diabetes mellitus use some form of complementary and alternative medicine. One plant that has received the most attention for its anti-diabetic properties is Momordica charantia commonly referred to as bitter gourd. In this study, bitter gourd was extracted in various media i.e. ethanol, water, citric acid, sodium carbonate and sodium chloride. The samples were evaluated for their in-vitro ability to inhibit α-amylase and α-glucosidase enzymes activity. Ethanol extract was observed to have maximum inhibition against these enzymes. The IC50 values recorded for inhibition of α-amylase activity were 81.34, 87.56, 83.89, 97.71 and 83.12 μg/ml respectively for crude extracts of ethanol, water, citric acid, Na2CO3 and NaCl. Similarly, the ability of extracts to inhibit α-glucosidase was reflected in the result pattern ethanol<Na2CO3<NaCl<aqueous<citric acid (i.e. 72.81<75.66<80.15<81.22<83.85 μg/ml). Therefore, ethanol extract has potential applications in developing drug therapy for the treatment of diabetes using bitter gourd.

Download Full-text